A large number of studies in recent years has shown that the cancer incidence of diabetes patients who take metformin has been quite low, and metformin is associated with the decline of cancer mortality compared to insulin and sulfonylureas for diabetes; for lung cancer patients, the survival of patients with stage IV lung cancer complicated with diabetes has been significantly increased after taking metformin.
